- 期刊
Analysis of First Year Mortality in Stage III Esophageal Cancer Patients Treated with Concurrent Chemoradiotherapy
第三期食道癌患者經同步化放療後的第一年死亡分析
摘要
局部晚期食道癌的治療包括手術、放射治療、以及化學治療，多數患者接受跨領域之間的合併治療。在台灣食道癌在診斷後第一年的存活率不到五成，代表許多患者可能在尚未接受治療、治療中、及治療結束後的近期內死亡，了解第一年內的死亡原因相形重要。本研究根據AJCC第七版分期，分析47例曾接受同步化放療的第三期食道癌患者，在診斷後第一年內死亡的18個案例。其中10例（56%）有腫瘤惡化，多為遠處轉移；13例（72%）直接死因為感染，1例（6%）為食道大動脈瘻管，1例（6%）為食道縱膈腔瘻管，1例（6%）為疾病惡化，1例（6%）為社會案件，1例（6%）為腦梗塞。未來需要更多的研究分析同步化放療後早期的死亡及併發症以改善食道癌的治療成果。
並列摘要
Medical practitioners currently have several management options to treat locally advanced esophageal cancer, including surgery, radiation therapy, and chemotherapy. However, most patients had multidisciplinary treatment. In Taiwan, the one-year survival rate of esophageal cancer was less than 50%. This phenomenon may be due to patient mortality before therapy, during therapy, or early after the completion of therapy. Because of this elevated mortality rate, it is important to illustrate the cause of mortality in the first year. We analyzed 47 locally advanced stage III esophageal cancer patients who had received concurrent chemoradiotherapy (CCRT) in our hospital. Eighteen of them died in the first year after diagnosis. Ten patients (56%) had tumor progression (primarily distant metastasis), 13 patients (72%) died directly from infection, 1 patient (6%) died from main artery esophageal fistula, 1 patient (6%) died from esophageal mediastinal fistula, 1 patient (6%) died solely from disease progression, 1 patient (6%) died from some kind of social event, and 1 patient (6%) died from ischemic stroke. Timely research to analyze the complications and mortality early after CCRT is relevant to improving treatment outcomes.
被引用紀錄
延伸閱讀
- 許軒之、梁雲、方富民、孫立民、陳惠君、王重榮（1994）。第三期後期子宮頸癌接受單獨放射線治療之結果。放射治療與腫瘤學，1(4)，321-327。https://doi.org/10.6316/TRO/199401(4)321
- 朱怡瑾、張湘媚（2016）。一位食道癌病人術後成功脫離呼吸器之照護經驗。高雄護理雜誌，33(1)，42-52。https://doi.org/10.6692/KJN-2016-33-1-5
- Yang, H. H., Liu, M. T., Pi, C. P., Chang, T. H., Huang, C. Y., & Huang, C. C. (2011). FIGO第三期到第四期子宮頸癌患者接受同步化學放射治療後的結果與預後因子分析. 放射治療與腫瘤學, 18(4), 275-286. https://doi.org/10.6316/TRO/201118(4)275
- 關如珺（2019）。Durvalumab：無法手術切除的第三期非小細胞肺癌於放射治療合併化療後之鞏固治療。腫瘤護理雜誌，19(2)，57-66。https://doi.org/10.6880/TJON.201912_19(2).04
- Liao, C. K., Yeh, C. Y., MingTsang, Y., Lin, G. P., Tang, R. P., Chiang, J. M., You, Y. T., Hsieh, P. S., Tsai, W. S., Hung, H. Y., You, J. F., Chiang, S. F., Lai, C. C., & Chen, J. S. (2017). 手術前長程化學與放射治療較手術前短程放射治療對於第三期直腸癌病患的無病存活率有顯著的改善. 中華民國大腸直腸外科醫學會雜誌, 28(1), 18-26. https://doi.org/10.6312/SCRSTW.2017.28(1).10519